NeoPredics
Predictive analytics and clinical decision-support company focused on neonatal, maternal, and perinatal risk.
What They Do
NeoPredics develops predictive algorithms and software for maternal and neonatal clinical decision support, including neonatal bilirubin trajectory forecasting and preeclampsia risk prediction (PreFree). The company uses “NeoPredics” and “NeoPredix” inconsistently in public materials; the canonical display name is NeoPredics.
Competitive Position
NeoPredics competes in the neonatal and maternal clinical decision support space, differentiated by specific prediction tools (bilirubin trajectory, preeclampsia) rather than broad monitoring platforms. The CE-market launch of PreFree in October 2025 gives the company a European regulatory pathway ahead of potential FDA engagement.
Funding Rounds
No funding rounds on record for this company.